Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jean Carlos,Lipreri da Silva

第一单位： Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

作者： Jean Carlos,Lipreri da Silva ^[1] ; Keli,Lima ^[2] ; Benjamin,Ede ^[3] ; Mariana,Lazarini ^[4] ; Hugo Passos,Vicari ^[1] ; Frederico Lisboa,Nogueira ^[2] ; Natasha S,Clayton ^[3] ; Katy,Pinnell ^[3] ; Wellington Fernandes da,Silva ^[2] ; Elvira Deolinda Rodrigues Pereira,Velloso ^[2] ; Israel,Bendit ^[2] ; Leticia Veras,Costa-Lotufo ^[1] ; Eduardo Magalhães,Rego ^[2] ; Anne J,Ridley ^[3] ; João Agostinho,Machado-Neto ^[5]

作者单位： Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. ^[1] Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil. ^[2] School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom. ^[3] Department of Clinical and Experimental Oncology, Federal University of São Paulo, São Paulo, Brazil. ^[4] Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: jamachadoneto@usp.br. ^[5]

关键词 Acute lymphoblastic leukemia Cytoskeleton Ezrin Rho GTPases